Cargando…

Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease

Approximately 35–40% of patients with classic infantile Pompe disease treated with enzyme replacement therapy (ERT) develop high, sustained antibody titers against the therapeutic enzyme alglucosidase alfa, which abrogates the treatment efficacy. Induction of antigen-specific immune tolerance would...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Baodong, Banugaria, Suhrad G., Prater, Sean N., Patel, Trusha T., Fredrickson, Keri, Ringler, Douglas J., de Fougerolles, Antonin, Rosenberg, Amy S., Waldmann, Herman, Kishnani, Priya S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121343/ https://www.ncbi.nlm.nih.gov/pubmed/27896120 http://dx.doi.org/10.1016/j.ymgmr.2014.08.005

Ejemplares similares

Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT
por: Banugaria, Suhrad G., et al.
Publicado: (2013)

Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy
por: Prater, Sean N, et al.
Publicado: (2013)

CRIM-negative infantile Pompe disease: Characterization of immune responses in patients treated with ERT monotherapy
por: Berrier, Kathryn L., et al.
Publicado: (2015)

Enzyme replacement therapy (ERT) in pompe disease
por: Fiumara, Agata
Publicado: (2014)

S3.1 Are there ERT defined guidelines for Pompe disease?
por: Toscano, Antonio, et al.
Publicado: (2011)

Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid α-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease
por: Lim, Jeong-A, et al.
Publicado: (2019)

Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent
por: Nayak, Sushrusha, et al.
Publicado: (2014)

Dysregulation of Multiple Facets of Glycogen Metabolism in a Murine Model of Pompe Disease
por: Taylor, Kristin M., et al.
Publicado: (2013)

New Insights into Gastrointestinal Involvement in Late-Onset Pompe Disease: Lessons Learned from Bench and Bedside
por: Korlimarla, Aditi, et al.
Publicado: (2021)

Effect of enzyme replacement therapy (ERT) added to Home Mechanical Ventilation (HMV) in Adult Pompe disease
por: Sayeed, Nadia, et al.
Publicado: (2015)

Positive Impact of Home ERT for Mucopolysaccharidoses and Pompe Disease: The Lesson Learnt from the COVID-19 Pandemic
por: Fiumara, Agata, et al.
Publicado: (2023)

An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease
por: Kazi, Zoheb B., et al.
Publicado: (2018)

The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients
por: Feeney, Erin J, et al.
Publicado: (2014)

A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease
por: Lim, Han-Hyuk, et al.
Publicado: (2017)

Pompe disease- experience from South India
por: Lingappa, Lokesh, et al.
Publicado: (2013)

Long term outcome and clinical experience on immune tolerance induction therapies in infantile Pompe disease
por: Austin, Stephanie, et al.
Publicado: (2013)

Behavioral, social and school functioning in children with Pompe disease
por: Korlimarla, Aditi, et al.
Publicado: (2020)

L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report
por: Rovelli, Valentina, et al.
Publicado: (2022)

Successful twin pregnancy in a 38-year-old woman with Pompe disease despite interruption of enzyme replacement therapy (ERT)
por: Tiling, N, et al.
Publicado: (2013)

Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2017)

Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2019)

Enzyme Replacement Therapy (ERT) on Heart Function Changes the Outcome in Patients with Infantile-Onset Pompe Disease: A Familial History
por: Lecis, Marco, et al.
Publicado: (2023)

Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort
por: Desai, Ankit K., et al.
Publicado: (2020)

Pregnancy Outcomes in Late Onset Pompe Disease
por: Goker-Alpan, Ozlem, et al.
Publicado: (2020)

The Pompe Registry: tracking Pompe disease symptoms in a broad patient population
por: Byrne, B, et al.
Publicado: (2008)

Adenotonsillectomy should be avoided whenever possible in infantile-onset Pompe disease
por: Jones, Harrison N., et al.
Publicado: (2020)

Monitoring and Management of Respiratory Function in Pompe Disease: Current Perspectives
por: El Haddad, Léa, et al.
Publicado: (2023)

Clinical laboratory experience of blood CRIM testing in infantile Pompe disease
por: Bali, Deeksha S., et al.
Publicado: (2015)

Muscle ultrasound in patients with late-onset Pompe disease identified by newborn screening
por: Jackson, David G., et al.
Publicado: (2023)

Measurement Properties of 2 Novel PROs, the Pompe Disease Symptom Scale and Pompe Disease Impact Scale, in the COMET Study
por: Dimachkie, Mazen M., et al.
Publicado: (2023)

GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry
por: Reuser, Arnold J. J., et al.
Publicado: (2019)

Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy
por: Desai, Ankit K., et al.
Publicado: (2019)

Immune tolerance strategies in siblings with infantile Pompe disease — Advantages for a preemptive approach to high-sustained antibody titers
por: Stenger, Elizabeth O., et al.
Publicado: (2015)

Assessment of Dysphonia in Children with Pompe Disease Using Auditory-Perceptual and Acoustic/Physiologic Methods
por: Crisp, Kelly D., et al.
Publicado: (2021)

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease
por: De Groot, Anne S., et al.
Publicado: (2021)

Small-Fiber Neuropathy in Pompe Disease: First Reported Cases and Prospective Screening of a Clinic Cohort
por: Hobson-Webb, Lisa D., et al.
Publicado: (2015)

Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease
por: Wang, Jason, et al.
Publicado: (2021)

Pompe disease diagnosis and management guideline
por: Kishnani, Priya S., et al.
Publicado: (2006)

A Race Against Time—Changing the Natural History of CRIM Negative Infantile Pompe Disease
por: Gupta, Punita, et al.
Publicado: (2020)

Suppression of pullulanase-induced cytotoxic T cell response with a dual promoter in GSD IIIa mice
por: Lim, Jeong-A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mdol073u3corl3o9gqk08if0l8